Aradigm Corporation Presents Phase 1 and Phase 2 Data on Inhaled Liposomal Ciprofloxacin in Healthy Volunteers and Cystic Fibrosis Patients at the 32nd European Cystic Fibrosis Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTCBB:ARDM) ("Aradigm") today announced it is presenting data from its Phase 1 study in healthy volunteers and Phase 2a study of inhaled liposomal ciprofloxacin in cystic fibrosis (CF) patients at the 32nd European Cystic Fibrosis Conference in Brest, France.
MORE ON THIS TOPIC